Cupressus arizonica pollen allergy immunotherapy - ALK-Abello

Drug Profile

Cupressus arizonica pollen allergy immunotherapy - ALK-Abello

Alternative Names: Arizona cypress pollen allergy immunotherapy; AVANZ Cupressus; Cupressus pollen allergy immunotherapy; Polen de Cupressus arizonica immunotherapy

Latest Information Update: 15 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ALK-Abello
  • Class Allergens; Antiallergics; Tree pollen allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Allergic rhinoconjunctivitis

Most Recent Events

  • 25 Nov 2016 Launched for Allergic rhinoconjunctivitis in Spain before November 2016 (SC) (ALK-Abello email communication)
  • 01 Nov 2014 ALK-Abello completes a phase II trial in Allergic rhinoconjunctivitis in Spain (NCT02069535)
  • 28 Aug 2014 CTP push (NCT02069535)- now recruiting, removed EudraCT2013-001728-20 from profile as this record no longer contains info related to Cupressus immunotherapy (RDI 39488), changed phase date to match NCT02069535 & changed phase from II/III to II as per NCT and updated Eudra record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top